Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.
Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.
National Hospital for Neurology and Neurosurgery, Queen Square, London
National Hospital for Neurology and Neurosurgery, Queen Square, London
Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.